Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Enlivex Therapeutics Ltd.
Enlivex Therapeutics Ltd. News
Enlivex Therapeutics Ltd. Quantitative Score
About Enlivex Therapeutics Ltd.
Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Nes Ziona, Israel.
Enlivex Therapeutics Ltd. Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
Enlivex Therapeutics Ltd. Financials
Table Compare
Compare ENLV metrics with: | |||
|---|---|---|---|
Earnings & Growth | ENLV | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | ENLV | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | ENLV | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | ENLV | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Enlivex Therapeutics Ltd. Income
Enlivex Therapeutics Ltd. Balance Sheet
Enlivex Therapeutics Ltd. Cash Flow
Enlivex Therapeutics Ltd. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Neutral |
| Return on Equity | Strong Sell |
| Return on Assets | Strong Sell |
| Debt/Equity Ratio | Neutral |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Buy |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Historical Market Cap
Shares Outstanding
Enlivex Therapeutics Ltd. Executives
| Name | Role |
|---|---|
| Shai Novik | Executive Chairman |
| Oren Hershkovitz | Chief Executive Officer |
| Dror Mevorach | Founder and Scientific Advisor |
| Shachar Shlosberger | Chief Financial Officer |
| Einat Galamidi | Chief Medical Officer |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Shai Novik | Executive Chairman | Male | 1966 | 528K |
| Oren Hershkovitz | Chief Executive Officer | 1977 | 273.6K | |
| Dror Mevorach | Founder and Scientific Advisor | 1956 | 180K | |
| Shachar Shlosberger | Chief Financial Officer | Female | 1977 | 126K |
| Einat Galamidi | Chief Medical Officer | 1974 | -- |
Enlivex Therapeutics Ltd. Insider Trades
| Date | 9 Oct |
| Name | Murray Michael Anthony |
| Role | former SVP - Operations |
| Transaction | Disposed |
| Type | S-Sale |
| Shares | 56390 |
| Date | 2 Jan |
| Name | WEATHERSON HARVEY D |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 12000 |
| Date | 2 Jan |
| Name | RANEY DENNIS R |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 12000 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 9 Oct | Murray Michael Anthony | former SVP - Operations | Disposed | S-Sale | 56390 |
| 2 Jan | WEATHERSON HARVEY D | Director | Acquired | A-Award | 12000 |
| 2 Jan | RANEY DENNIS R | Director | Acquired | A-Award | 12000 |